Molecular Pathways for Lymphangiogenesis and their Role in Human Disease

Decoding the Genomic Control of Immune Reactions

Volumn 281, Issue , 2007, Pages 38-49

  Stacker, Steven A ^a   Farnsworth, Rae H ^a   Karnezis, Tara ^a   Shayan, Ramin ^a   Smith, Darrin P ^a   Paavonen, Karri ^a   Davydova, Natalia ^a   Caesar, Carol ^a   Inder, Rachael ^a   Baldwin, Megan E ^a   Mccoll, Bradley K ^a   Roufail, Sally ^a   Williams, Richard A ^b   Hughes, Richard A ^c   Alitalo, Kari ^d,e   Achen, Marc G ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Lymphangiogenesis; Lymphangiogenic growth factors and understanding molecular mechanisms; Lymphangiogenic growth factors in cancer; Primary lymphoedema Milroy's disease; VEGF C VEGF D VEGFR 3 pathway in lymphangiogenesis

Indexed keywords

VASCULOTROPIN;

GENETICS; HUMAN; LYMPHANGIOGENESIS; METABOLISM; NEOPLASM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

HUMANS; LYMPHANGIOGENESIS; NEOPLASMS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 36348934688     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470062128.ch4     Document Type: Chapter

References (34)

1. Achen MG, Jeltsch M, Kukk E et al 1998 Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 95:548-553.
2. Achen MG, McColl BK, Stacker SA 2005 Focus on lymphangiogenesis in tumor metastasis. Cancer Cell 7:121-127.
3. Baldwin ME, Stacker SA, Achen MG 2002 Molecular control of lymphangiogenesis. Bioessays 24:1030-1040.
4. + glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 144:789-801.
5. Dumont DJ, Jussila L, Taipale J et al 1998 Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 282:946-949.
6. He Y, Rajantie I, Pajusola K et al 2005 Vascular endothelial cell growth factor receptor 3- mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res 65:4739-4746.
7. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF, Detmar M 2005 VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 201:1089-1099.
8. Jackson DG, Prevo R, Clasper S, Banerji S 2001 LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol 22:317-321.
9. Jeltsch M, Kaipainen A, Joukov V et al 1997 Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276:1423-1425.
10. Joukov V, Pajusola K, Kaipainen A et al 1996 A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15:290-298.
11. Joukov V, Sorsa T, Kumar V et al 1997 Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 16:3898-3911.
12. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S 2005 Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23:3706-3712.
13. Kajiya K, Hirakawa S, Ma B, Drinnenberg I, Detmar M 2005 Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J 24:2885-2895.
14. Karkkainen MJ, Ferrell RE, Lawrence EC et al 2000 Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet 25:153-159.
15. Karkkainen MJ, Haiko P, Sainio K et al 2004 Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 5:74-80.
16. Karpanen T, Egeblad M, Karkkainen MJ et al 2001 Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 61:1786-1790.
17. Makinen T, Veikkola T, Mustjoki S et al 2001a Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J 20:4762-4773.
18. Makinen T, Jussila L, Veikkola, T et al 2001b Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 7:199-205.
19. Mandriota SJ, Jussila L, Jeltsch M et al 2001 Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 20:672-682.
20. McColl BK, Baldwin ME, Roufail S et al 2003 Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D. J Exp Med 198:863-868.
21. Oliver G, Detmar M 2002 The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. Genes Dev 16:773-783.
22. Padera TP, Kadambi A, di Tomaso E et al 2002 Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296:1883-1886.
23. Siegfried G, Basak A, Cromlish JA 2003 The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J Clin Invest 111:1723-1732.
24. Skobe M, Hawighorst T, Jackson DG et al 2001 Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7:192-198.
25. Stacker SA, Stenvers K, Caesar C et al 1999 Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J Biol Chem 274:32127-32136.
26. Stacker SA, Caesar C, Baldwin ME et al 2001 VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7:186-191.
27. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K 2002 Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2:573-583.
28. Stacker SA, Hughes RA, Achen MG 2004a Molecular targeting of lymphatics for therapy. Curr Pharm Design 10:65-74.
29. Stacker SA, Williams RA, Achen MG 2004b Lymphangiogenic growth factors as markers of tumor metastasis. APMIS 112:539-549.
30. Veikkola T, Jussila L, Makinen T et al 2001 Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 20:1223-1231.
31. White JD, Hewett PW, Kosuge D et al 2002 Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res 62:1669-1675.
32. Yokoyama Y, Charnock-Jones DS, Licence D et al 2003 Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer 88:237-244.
33. Kaplan RN, Riba RD, Zacharoulis S et al 2005 VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438:820-827.
34. Maruyama K, Ii M, Cursiefen C et al 2005 Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest 115:2363-2372.